Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3267-3272

  Sviatoha, Vitali ^a   Tani, Edneia ^a   Ghaderi, Mehran ^a   Kleina, Regina ^b   Skoog, Lambert ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

Author keywords

BRAF; Fine needle aspiration; Melanoma; Proliferation

Indexed keywords

KI 67 ANTIGEN; B RAF KINASE; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; ASPIRATION BIOPSY; BRAF GENE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL; SUN EXPOSURE; ADULT; AGED; FINE NEEDLE ASPIRATION BIOPSY; GENETICS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; METABOLISM; MIDDLE AGED; MUTATION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77958547597     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Satyamoorthy K and Herlyn M: Cellular and molecular biology of human melanoma. Cancer Biol Ther 1: 14-17, 2002.
2. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J and Rapp UR: The ins and outs of Raf kinases. Trends Biochem Sci 19(11): 474-480, 1994.
3. Liang S, Sharma A, Peng HH, Robertson G and Dong C: Targeting mutant (V600E) BRAF in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 67: 5814-5820, 2007.
4. Li N, Batt D and Warmuth M: B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 8(6): 452-456, 2007. (Pubitemid 46868066)
5. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S and Hemminki K: BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9(9): 3362-3368, 2003. (Pubitemid 37082731)
6. Chang DZ, Panageas KS, Osman I, Polsky D, Busam K and Chapman PB: Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2(1): 46, 2004. (Pubitemid 40617844)
7. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI and Libutti SK: Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 5: 38, 2007.
8. Flaherty KT: Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 7(5): 617-626, 2007.
9. Zajicek J: Aspiration biopsy cytology. Cytology of supradiaphragmatic organs. In: Monographs in Clinical Cytology. vol 4. Wied GL. Basel: Karger, pp. 1-5, 1974.
10. Nasiell K, Tani E and Skoot L: Fine-needle aspiration cytology and immunocytochemistry of metastatic melanoma. Cytopathology 2: 137-147, 1991.
11. Barnhill RL: Malignant Melanoma. In: Pathology of Melanocytic Nevi and Malignant melanoma. Raymond L. Barnhill, Butterworth-Heinemann, 1995.
12. Skoog L, Rutqvist LE and Wilking N: Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 31(2): 139-141, 1992.
13. Tani EM, Christerson B, Porwit A and Skoog L: Immunocytochemical analysis and cytomorphologic diagnosis on fine-needle aspirates of lymphoproliferative diseases. Acta Cytol 32: 209-215, 1988. (Pubitemid 18091151)
14. Livak KJ, Marmaro J and Todd JA: Towards fully automated genome-wide polymorphism screening. Nat Genet 9: 341-342, 1995.
15. Buzaid AC: Management of metastatic cutaneous melanoma. Oncology (Williston Park) 18(11): 1443-1450, 2004.
16. Atallah E and Flaherty L: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6(3): 185-93, 2005.
17. Dittrich C: Targeted therapy - How successful has it been? Eur J Cancer 40: 2016-2021, 2004.
18. Mercer K and Pitchhard C: Raf proteins and cancer: B-raf is identified as mutational target. Biochim Biophys Acta 1653: 25-40, 2003. (Pubitemid 36627818)
19. Rini BI: Sorafenib. Expert Opin Pharmacother 7(4): 453-461, 2006.
20. Lang L: FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134(2): 379, 2008.
21. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J and Andreeff M: Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3): 184-198, 2008.
22. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC and Figg WD: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14(1): 209-214, 2008.
23. Grávalos C, Cassinello J, Fernández-Rañada I and Holgado E: Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer 6(10): 691-699, 2007. (Pubitemid 350221366)
24. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D and Bastian BC: Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95(24): 1878-1890, 2003.
25. Sviatoha V, Rundrgen Å, Tani E, Hansson J, Kleina R and Skoog L: Expression of CD40, CD44, BCL-2 antigens and rate of cell proliferation on fine-needle aspirates from metastatic melanoma. Cytopathology 13: 11-21, 2002. (Pubitemid 34415653)